Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR2021
- Development stage
- Phase 1
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BR2021 is a small molecule drug developed by Boryung Corp. It is currently in Phase 1 clinical development, primarily targeting neoplasms, with a specific focus on pancreatic adenocarcinoma. The drug is also being investigated for potential use in digestive system disorders and endocrinology/metabolic diseases. As of early 2025, the main clinical trial underway compares the pharmacokinetics and safety of BR2021 versus a related formulation (BR2021-1) in patients with metastatic pancreatic adenocarcinoma. Detailed information about its mechanism of action or molecular target has not been disclosed publicly[1][2][4].
- Other names
- BR-2021BR2021BR 2021
Beyond the preview
Go deeper on BR2021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR2021.